Liquid chromatography and mass spectrometry instrument system

液相色谱、质谱仪器系统

• 批准号: 10415617
• 负责人: Francis Michael Sverdrup
• 金额: $ 24.95万
• 依托单位: SAINT LOUIS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10415617
• 关键词: Aging; Award; Biological Response Modifier Therapy; Central Nervous System Diseases; Communicable Diseases; Computer Workstations; Computer software; Consultations; Core Facility; Data; Data Analyses; Disease; Drug Kinetics; Ensure; Funding; Future; Genetic Diseases; Hepatitis B; Immunology; Institutes; Laboratories; Legal patent; Liquid Chromatography; Liver diseases; Lysosomal Storage Diseases; Malignant Neoplasms; Measures; Microbiology; Molecular; Muscular Dystrophies; Mycoses; Nitrogen; Performance; Pharmaceutical Preparations; Pharmacology; Program Development; Publications; Request for Applications; Research; Research Personnel; Saints; Services; Speed; Supervision; System; Technology; Testing; Time; Tuberculosis; United States National Institutes of Health; Universities; chronic pain; clinical translation; drug development; drug discovery; improved; in vitro Assay; in vivo; innovation; instrument; instrumentation; liquid chromatography mass spectrometry; mass spectrometer; member; neglect; repaired; success; time use

This instrument application requests funds to purchase a liquid chromatography (LC) / mass spectrometry (MS) system comprised of a SCIEX 4500 triple stage quadrupole (TSQ) mass spectrometer, Exion AC LC and autosampler, Peak nitrogen generator, and workstation computer. The proposed instrument will be housed in in the Saint Louis University (SLU) Department of Molecular Microbiology & Immunology and will be managed as a critical asset of the ADME/PK Core Services Group of the SLU Institute for Drug and Biotherapeutic Innovation (IDBI). This core offers access to expert pharmacology-related consultations and wet bench support to the more than 140 IDBI members engaged in drug discovery for diseases such as cancer; chronic pain; central nervous system disorders; liver disease; infectious diseases such as hepatitis B, tuberculosis, and fungal infections; genetic disorders including muscular dystrophy and lysosomal storage disease; and neglected diseases. Laboratory support is critically dependent on having functional and reliable tandem LC/MS instrument technology to perform the in vitro assays and in vivo studies that are commonly employed in the testing funnels of nearly every drug development program. Performance of these functions is currently dependent on an aging Sciex 4000 instrument system which has been in use for more than 14 years. Not only is it becoming more difficult to maintain and repair each year, but it also lacks the sensitivity, speed, and other improved technical specifications provided by newer redesigned instrument systems. The Sciex 4500 also comes with upgraded software platforms for acquiring and analyzing data. Thus, our primary needs for the Sciex 4500 instrument system are to ensure continuity and stability and to provide enhanced performance in support of the ongoing and future needs of our many users, knowing that our current instrument is approaching a time when it will no longer be serviceable. The university has made a strong commitment to the strategy of helping its researchers obtain key pharmacokinetic data as evidenced by the recent hiring of a highly skilled full time doctoral level analytical chemist, Dr. Abdul Mottaleb, who has extensive expertise using LC/MS to detect a wide variety of analytes. He is supervised by Dr. Griggs, the PI of this application, who is the Director of the core facility and a co-Director of the SLU IDBI. This application summarizes drug discovery research of 11 users of the current instrument system who will have an ongoing need for accurate and timely high-quality data from the new instrument. This includes four major users with a combined 7 active NIH awards that are expected to require over 60% of the instrument’s authorized usage time (AUT). The SLU-IDBI continues to promote ADME/PK services to new users to maximize their impact measured through increased publications, patents, and clinical translation of academic research. This new instrumentation system will ensure continued success of the important facility for the next 10 years.

该仪器申请要求资金购买液相色谱法（LC） /质谱法 （MS）系统完成SCIEX 4500三级四极杆（TSQ）质谱仪，驱动AC LC和 自动采样器，峰值氮发生器和工作站计算机。提议的工具将安置在 在圣路易斯大学（SLU）分子微生物学和免疫学系，将管理 作为SLU药物与生物治疗研究所的ADME/PK核心服务小组的关键资产 创新（IDBI）。该核心提供了与专家药理学相关咨询和湿台的访问权限 支持140多名IDBI成员从事癌症疾病的药物发现；慢性的 疼痛;中枢神经系统疾病；肝病；传染病，例如丙型肝炎，结核病和 真菌感染；遗传疾病，包括肌肉营养不良和溶酶体储存疾病；和 被忽视的疾病。实验室支持在关键取决于具有功能和可靠的串联 LC/MS仪器技术进行体外测定和体内研究，通常在 几乎每个药物开发计划的测试渠道。这些功能的性能目前是 取决于已经使用了超过14年的老化Sciex 4000仪器系统。不仅 每年维护和维修变得越来越困难，但也缺乏灵敏度，速度和其他 改进的技术规格由较新的重新设计的仪器系统提供。 Sciex 4500也 随附用于加速和分析数据的升级软件平台。那，我们对 Sciex 4500仪器系统将确保连续性和稳定性，并提供增强的性能 知道我们当前的工具正在接近我们许多用户的持续和未来需求 它将不再有用的时间。该大学对 帮助其研究人员获得关键的药代动力学数据，最近雇用了高技能的全面 时间博士学位分析化学家Abdul Mottaleb博士，他使用LC/MS进行广泛的专业知识来检测 各种各样的分析物。他由Griggs博士（该申请的PI）监督，他是 核心设施和SLU IDBI的联合导演。该申请总结了11的药物发现研究 当前的仪器系统的用户将持续需要准确，及时的高质量数据 从新乐器。这包括四个主要用户，共有7个主动NIH奖项 预计将需要该仪器授权使用时间的60％以上（AUT）。 slu-idbi继续 向新用户推广ADME/PK服务，以最大程度地提高其通过增加的出版物来衡量的影响， 专利和学术研究的临床翻译。这个新的仪器系统将确保继续 未来10年的重要设施的成功。